Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DUPONT DISCONTINUING SALE OF RAW MATERIALS TO MAKERS OF PERMANENT IMPLANTS

This article was originally published in The Gray Sheet

Executive Summary

DUPONT DISCONTINUING SALE OF RAW MATERIALS TO MAKERS OF PERMANENT IMPLANTS, the firm says in a Jan. 15 letter to its customers. "As of Jan. 15, 1993, DuPont will begin to phase out sale of materials to customers using our materials in medical articles intended for permanent implantation in the human body or in permanent contact with internal body fluids or tissues," the letter states. The firm intends to "complete the phase out as soon as possible, but no later than Jan. 31, 1994." The company explains in the letter that "unpredictable and excessive costs of doing business with the manufacturers of implantable medical devices no longer justifies unrestricted sale of standard raw materials." DuPont says it will continue to honor its existing supplier agreements during the phase out period in order to allow customers affected by the announcement time to find alternate suppliers of the materials, "or alternate materials." In addition, the letter notes that DuPont will "restrict sales of materials to companies who use those materials in medical articles intended for brief or temporary implantation in the human body or in contact with internal body fluids or tissues." DuPont defines a temporary implant as remaining in the body less than 30 days. The letter says that the firm will not supply materials to temporary implant manufacturers "unless the material comes directly from DuPont under a contract which expressly acknowledges the contemplated use and contains specific business risk management requirements." Manufacturers impacted by the policy are asked to contact DuPont by March 1. The firm adds that "it is DuPont's intention to implement this policy in such a way that it does not cause negative economic or safety effects in the health industry, which provides essential benefits to people." Among the numerous raw materials supplied by DuPont is Teflon, which is used in a number of medical devices.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel